Epidemiology of influenza A (H1N1)pdm09-associated deaths in the United States, September-October 2009

Influenza Other Respir Viruses. 2012 Nov;6(6):e169-77. doi: 10.1111/j.1750-2659.2012.00408.x. Epub 2012 Jul 16.

Abstract

Background: From April to July 2009, the United States experienced a wave of influenza A (H1N1)pdm09 virus (H1N1pdm09) infection. The majority of the deaths during that period occurred in persons <65 years of age with underlying medical conditions.

Objective: To describe the epidemiology of H1N1pdm09-associated deaths in the US during the fall of 2009.

Methods: We collected demographic, medical history, and cause of death information on a nationally representative, stratified random sample of 323 H1N1pdm09-associated deaths that occurred during September 1-October 31, 2009.

Results: Data were available for 302/323 (93%) deaths. Most cases (74%) were 18-64 years of age and had ≥ 1 underlying medical condition (72%). Among cases aged <18 years, 16/43 (37%) had a chronic lung disease, and 15/43 (35%) a neurological disorder; among cases aged ≥ 18 years, 94/254 (37%) had a chronic lung disease and 84/254 (33%) had a metabolic disorder. The median number of days between symptom onset and death was six among children (range, 1-48) and 12 among adults (range, 0-109). Influenza antiviral agents were prescribed for 187/268 (70%) of cases, but only 48/153 (31%) received treatment within 2 days of illness onset.

Conclusions: The characteristics of H1N1pdm09 deaths identified during the fall of 2009 were similar to those occurring April-July 2009. While most cases had conditions that were known to increase the risk for severe outcomes and were recommended to receive antiviral therapy, a minority of cases received antivirals early in the course of illness.

MeSH terms

  • Adolescent
  • Adult
  • Aged
  • Aged, 80 and over
  • Antiviral Agents / therapeutic use
  • Child
  • Child, Preschool
  • Female
  • Humans
  • Infant
  • Infant, Newborn
  • Influenza A Virus, H1N1 Subtype / isolation & purification*
  • Influenza A Virus, H1N1 Subtype / pathogenicity
  • Influenza, Human / drug therapy
  • Influenza, Human / epidemiology*
  • Influenza, Human / mortality*
  • Influenza, Human / virology
  • Male
  • Middle Aged
  • Risk Factors
  • Survival Analysis
  • Time Factors
  • United States / epidemiology
  • Young Adult

Substances

  • Antiviral Agents